Intradermal delivery is safe

Over the years, Intradermal Delivery has been proved to be very safe with none to minor adverse effects.
Studies have found that intradermal vaccination may be associated with a greater incidence of local reactogenicity that typically resolves quickly.
Adverse events primarily include local mild pain, swelling, and redness, but no systemic reactions*, minimal downtime and bruising, little to no bleeding at all.

For Adverse Events and Contraindications and Warnings and Precautions please see MicronJetTM Instruction for Use

*Marra F, Young F et al. meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Influenza Other Respir Viruses 2013; 7:584-603;

Extensive clinical experience

Wide range of clinical trials with a variety of vaccines and drugs

One of the largest intradermal vaccination databases in industry

Numerous Trials

In addition to global commercial sales, NanoPass’s MicronJetTM Technology has been used to administer over 30,000 injections to approximately 7,500 patients in over 70 completed and ongoing clinical trials

Validated Benefits

MicronJetTM has demonstrated a superior immune response with full dose and equivalence or a trend for superiority with lower doses (4-40%)

Consistent and shallow intradermal delivery

Due to its unique design the MicronJetTM’s Intradermal Delivery devices are one of the shallowest and most consistent forms of intradermal delivery in healthcare history.
The easy-to-use MicronJetTMTM is barely visible to the naked eye makes it also significantly less painful than standard needl injections, as well as much less intimidating.
Using MicronJet 600TM and MicronJet 800TM requires a short learning curve, enabling clinicians to quickly learn how to use the device, and adopt it as a leading alternative.

  • Blebs of >6 mm were observed 99% of the time, evaluated in over 1,000 injections on more than 800 subjects
  • Significantly less painful and intimidating than a regular needle and syringe, with the potential for improved compliance
  • Pediatrics applicability, as demonstrated by large Phase III study on 6-week-old infants
  • Smallest hollow needle in the market allows for a practically painless injection

Virtually Pain Free Delivery

As the smallest hollow needle in the market (just 0.6mm/ 0.8mm long), MicronJetTM microneedle allows for a virtually painless intradermal delivery, maximizing comfort and compliance.

Keeping comfort in mind

Virtually pain- free
Less intimidating
Tested in wide age range

MicronJetTM is available globally.